Isolinderalactone suppresses the progression of cholangiocarcinoma by modulating the CARMA1-BCL10-MALT1 signalosome
Journal of Biological Chemistry · 2026
DOI: 10.1016/j.jbc.2026.113162 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2026. Verfasst von Wangyang Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, Hangzhou, Zhejiang Province, Chi…. Hauptthemen laut MEDLINE: Cholangiocarcinoma, B-Cell CLL-Lymphoma 10 Protein, Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein, CARD Signaling Adaptor Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Zhejiang Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Cholangiocarcinoma (CCA) is a highly aggressive malignancy with poor prognosis and limited therapeutic options. While isolinderalactone (ILL) has shown anticancer potential, its effects and underlying mechanisms in CCA remain unclear. This study investigated the anti-CCA activity of ILL and elucidated its molecular mechanisms. ILL significantly inhibited CCA cell viability, proliferation, migration, and invasion, while also inducing G0/G1 cell cycle arrest and promoting apoptosis. Transcriptomic and biochemical analyses revealed that ILL suppressed the NF-κB signaling pathway by inhibiting IκB phosphorylation and p65 activation. Mechanistically, ILL was found to directly bind to BCL10, a key adaptor protein. This interaction disrupted the formation of the CARMA1-BCL10-MALT1 signalosome and consequently reduced BCL10 ubiquitination. Functional experiments confirmed this mechanism: BCL10 knockdown mimicked ILL's inhibitory effects, while a BCL10 mutation abolished them. Furthermore, activation of NF-κB with diprovocim partially reversed ILL's suppressive effects. In a xenograft nude mouse model, ILL effectively reduced tumor growth without significant toxicity and suppressed NF-κB activation in tumor tissues. These findings demonstrate that Isolinderalactone suppresses CCA progression by modulating the CARMA1-BCL10-MALT1 signalosome and BCL10 ubiquitination to regulate the NF-κB pathway, supporting its potential as a promising therapeutic candidate for CCA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, Hangzhou, Zhejiang Province, China; Hangzhou Institute of Digestive Diseases, Hangzhou, Zhejiang Provi…
Förderung
- Natural Science Foundation of Zhejiang Province
- National Natural Science Foundation of China
Zitieren
APA
Chen, W., Xu, D., Liu, Q., Wang, X., Xu, C., Zhu, Y., Lin, W., Zhang, H., Zhang, X., Yang, J., & Shen, H. (2026). Isolinderalactone suppresses the progression of cholangiocarcinoma by modulating the CARMA1-BCL10-MALT1 signalosome. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2026.113162
Vancouver
Chen W, Xu D, Liu Q, Wang X, Xu C, Zhu Y, et al. Isolinderalactone suppresses the progression of cholangiocarcinoma by modulating the CARMA1-BCL10-MALT1 signalosome. Journal of Biological Chemistry. 2026. doi:10.1016/j.jbc.2026.113162
BibTeX
@article{Chen2026,
author = {Chen, Wangyang and Xu, Dongchao and Liu, Qiang and Wang, Xuehui and Xu, Chenshan and Zhu, Yuanling and Lin, Wenjun and Zhang, Hongchen and Zhang, Xiaofeng and Yang, Jianfeng and Shen, Hongzhang},
title = {Isolinderalactone suppresses the progression of cholangiocarcinoma by modulating the CARMA1-BCL10-MALT1 signalosome},
journal = {Journal of Biological Chemistry},
year = {2026},
doi = {10.1016/j.jbc.2026.113162}
}
EUVIMED